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Abstract
It is proven that folic acid supplied in the periconceptional period can lower the recurrence and occurrence rate of neural tube 
defects (NTDs). Our research team on prevention of birth defects could demonstrate that folic acid preventable N TD s are partly 
based on hyperhomocystinemia and a genetic predisposition (mutation o f the metliylenetetrahydrofolate-reductase gene (MTHF- 
R)). Reduced activity of the folate méthylation cycle seems to be an attractive working hypothesis in the aetiology o f NTDs. This 
genetic metabolic defect can be overcome by treatment with folic acid and/or vitamin B12. © 1997 Elsevier Science Ireland Ltd. 
All rights reserved
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1. Folates are not only important for the treatment of 
megaloblastic anemia
Obstetricians are familiar with folates (folic acid) 
because of their central role together with iron in the 
treatment of anaemia especially during pregnancy. But 
folates are also necessary for numerous cellular func­
tions. There is now ample evidence that folic acid is of 
importance for the prevention of birth defects, particu­
larly neural tube defects (NTDs).
It has long been suspected that nutrition played a 
role in the cause of NTDs with emphasis on folic acid 
[1,2].
Observational reports indeed demonstrate folate defi­
ciency judged by the FIG LU  test and later serum and 
red cell folate in women with NTD offspring. These 
‘deficiencies5 led to intervention with multivitamins 
demonstrating a ten-fold reduction of the recurrence of 
NTD [3]. Our research group at the University of 
Nijmegen started in 1983 on the topic of primary 
prevention of birth defects, in particular NTDs.
* Tel.: +31 24 3614725; fax: + 31  24 3541194; e-mail: 
G.Theunissen@obgyn.azn.nl
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2. Folic acid reduces the recurrence and occurrence 
rates of NTDs
These observations called for a randomised trial to 
prove or disprove the benefit of folic acid.
A randomised double-blind prevention trial was car­
ried out in 33 centres [4]. Hungary contributed 769 
women to the total group of 1817 women (42%). These 
women were at risk of having a pregnancy with NTD, 
because of a previous affected pregnancy. They were 
allocated at random before pregnancy to one of three 
groups: (i) folic acid (4 mg); (ii) other vitamins; (iii) 
both folic acid and other vitamins and (iv) neither folic 
acid or other vitamins. Each group used their pills from 
at least 1 month before conception until the 12th week 
of pregnancy. A completed pregnancy was achieved in 
1195 women; six NTDs occurred in the folic acid 
groups and 12 in the two other groups, A  72% protec­
tive effect was calculated (relative risk, 0.28; 95% confi­
dence interval (CI93%> 0.12-0.71)). Compliance of 
tablets was studied by determining folic acid in blood 
samples.
Czeizel and Dudas (1992) [5] studied the extent to 
which vitamin supplementation could reduce the first 
occurrence of NTD. Women planning in most cases the 
first pregnancy were randomly assigned to receive a
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single tablet of a vitamin supplement (containing 12 
vitamins including 0,8 mg of folic acid, four minerals 
and three trace elements) or a trace-element supplement 
(containing copper, manganese, zinc and a very low 
dose of vitamin C) daily for at least 1 month before 
conception and until the date of the second missed 
menstrual period or later. Compliance was not deter­
mined, Pregnancy was confirmed in 4753 women. Con­
genital malformations were significantly more prevalent 
in the group receiving the trace-element supplement 
than in the vitamin-supplement group (22.9/1000 vs. 
13.3/1000, P  — 0.02).
There were six cases of NTDs in the group receiving 
the trace elements, as compared with none in the vita­
min supplement group (P  = 0.029). The authors con­
cluded that periconceptional vitamin use decreases the 
incidence of a first occurrence of NTDs.
The interest in folic acid has now been raised by the 
startling finding that folic acid c.q. multivitamins can 
prevent the recurrence and occurrence of NTDs.
3. The neural tube of the human is closed 4 weeks 
post-conception
The neural groove and folds are first seen during 
Carnegie stage 8, i.e. about 18 post-ovulatory days. The 
three main divisions of the brain appear at stage 9, The 
neural folds begin to fuse at stage 10. The rostral 
(anterior) neuropore closes within a few hours during 
stage 11 (about 24 post-ovulatory days). The caudal 
neuropore closes during stage 12 (about 26 days). At 
stage 13 (4 weeks) the neural tube is completely closed 
[6]-
Clinically seen this means that the development and 
closure of the neural tube takes place very early in 
human pregnancy.
Recently, genes have been identified whose expres­
sion marks the formation and regionalization of the 
neural plate and which encode cell adhesion molecules 
or putative transcription factors [7],
The major classes of NTD are anencephaly, en- 
cephalocoele and spina bifida. The yearly number of 
affected babies is about 400 000 worldwide, with a wide 
range (0.5-12/1000) among different countries [8].
Most cases (92%) of isolated NTD do have a multi­
factorial origin. The multiple or syndromic NTD group 
include chromosomal aberrations (trisomia 18), gene 
mutations (Meckel syndrome) and teratogenic medica­
tion (valproic acid).
4. Folic acid plays a keyrole in one carbon metabolism
Folic acid or vitamin Bn was first recognized in 1930 
as a factor present in the yeast preparation marmite,
which was able to cure megaloblastic anemia. The term 
‘folic acid’ is derived from the latin word folium which 
means ‘leaf. The substance was successfully synthesized 
in the form of pteroylmonoglutamate.
The major dietary sources of folates are fresh and 
green leafy vegetables, liver, kidney, asparagus, citrus 
fruits, juice whole wheat bread and legumes (wheat and 
dry beans).
The absorption process of dietary folate includes the 
conversion of poly glut am ates to mono glutamates and a 
full reduction to tetrahydrofolate (THF), the parent 
compound for all biological active folates. The predom­
inant folate in serum and in tissues is 5-methyl-THF.
Folate is involved in two cycles, one involving DNA 
biosynthesis (guanine, adenine and thymine), essential 
for cell division, the other being the méthylation cycle 
(or one carbon metabolism), essential for the provision 
of methylgroups for a wide range of cellular methyl- 
transferases (Fig. 1) [9],
5. Folate is an important substrate in the metabolism 
of homocysteine
Homocysteine is a sulfur-containing amino-acid, 
formed after déméthylation of the essential amino acid 
methionine (Fig. 2) [10]. Intracellular homocysteine is 
bound with serine to form cystathionine. This reaction 
is catalyzed by the enzyme cystathionine ß synthase 
(CBS). Cystathionine is then split to cysteine through 
the transsulphuration pathway. Homocysteine can also 
be remethylated.
Three B-vitamins are involved in methionine-homo- 
cysteine metabolism: B6 (pyridoxal 5' phosphate), Bn 
(folate) and Bn . The enzyme CBS requires vitamin B6 
as a co-factor. Methionine synthase (MS) requires vita­
min B12 as a cofactor and 5-methyl-THF as a substrate. 
Methyl-THF is formed upon the reduction of 5,10- 
methylene-THF (MTHF) catalyzed by methylenete- 
trahydrofolate reductase (MTHFR).
Thus, vitamin B6 is important in homocysteine 
transsulfuration, while folate and B12 play a significant 
role in homocysteine remethylation.
Defective trans-sulphuration as well as remethylation 
disorders will result in increased blood (hyperhomocys- 
teinaemia) and urine levels of homocysteine.
Classic homocystinuria is the homozygous form of 
the autosomal recessively inherited cystathionine syn­
thase deficiency. The clinical characteristics are prema­
ture atherosclerosis and thrombosis, ectopic lentis,
*  *
scoliosis, marfanoid features and mental retardation 
[ 1 1 ] 'As folate is an important substrate in the metabolism 
of homocysteine, it was suggested that a subset of NTD 
might be due to a maternal disturbance in this 
metabolism [12]. Furthermore, it was thought that ho-
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Fig, 1. The méthylation cycle. The central form of folate is the fully reduced form, THF, THF can accept a single carbon unit from serine, so 
converting itself to 5,10-MTHF. The conversion to 5-methyl-THF is made possible through the enzyme methylenetetrahydrofolate reductase 
(MTHFR). Homocysteine can than be remethylated through the vitamin B,2 dependent methionine synthase (MS) to methionine, thereby 
completing the méthylation cycle. Methionine will produce together with ATP S-adenosyl-methionine (SAM). SAM is used to methylate a wide 
range of substrates including myelin basic proteins, lipids, DNA and RNA (Ref 9, with permission).
mocysteine levels could give a rather accurate picture of 
vitamin B status.
Hyperhomocysteinaemia could be the result of inade­
quate nutrition or of an inborn error of metabolism.
In our studies total homocysteine was determined in 
plasma using high pressure liquid chromatography
(HPLC) [13].
Folate concentrations were measured in serum and 
red blood cells, and vitamin BI2 levels in serum, by 
using the Dualcount Solid Phase Boil Radioassay (Di­
agnostic Products, Los Angeles, CA). The assay of 
vitamin B6 as pyridoxal phosphate in whole blood was 
performed with HPLC.
Steegers-Theunissen et al (1994) [14] studied 41 non­
pregnant women who had given birth to infants with an 
NTD, as well as 50 control women who previously had 
normal offspring. Fasting plasma homocysteine concen­
trations were significantly higher in the NTD group. 
The concentrations of plasma folic acid, vitamin Bl2 
and pyridoxal 5' phosphate were not significantly differ­
ent in the two groups. Following an oral methionine 
load (0.1 g/kg body weight), plasma homocysteine con­
centrations were significantly higher in the NTD group 
than in controls. In nine (22%) patients from the NTD 
group, post load plasma homocysteine concentrations 
exceeded the mean plus twice the standard deviation of 
controls. All nine of these women had fibroblast cys­
tathionine synthase activities within the reference range. 
The authors suggested that not the trans-sulfuration 
but the remethylation pathway could be impaired in 
these women.
Supportive evidence linking impeded homocysteine 
remethylation to increased risk for NTD was published 
by Mills et al. (1995) [15]. Mothers with N TD  pregnan­
cies in the lower-normal serum vitamin B,2 range had 
less effective homocysteine metabolism (remethylation) 
compared with controls matched for vitamin status.
6. Thermolabile 5,10-MTHFR has been cloned, a 
mutation identified and recognised as an important 
genetic risk for NTD
The gene for M THFR has been cloned [16] and the 
DNA mutation responsible for the heat-labile variant
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Fig. 2. The metabolism of methionine in man (after Boers 1985) [10]. Methionine is demethylated in steps to homocysteine, Homocysteine can 
than enter the transsulphuration pathway leading to cysteine or be remethylated to methionine. For this remethylation folates and vitamin BJ2 
are essential.
has been identified [17]. The frequency of homozygotes 
for this polymorphism was 12% among French Canadi­
ans [18] and 5.4% in the Dutch population [17].
Fasting homocysteine levels were almost twice as 
high in homozygotes for this variant compared to those 
who did not have the polymorphic allele [18].
Van der Put et al. (1995) [19] studied the frequency of 
the 677 C -T  mutation in the 5,10-MTHF-R gene in 55 
patients with spina bifida and parents of such patients 
(70 mothers, 60 fathers). Five percent of 207 controls
were homozygous for the mutation compared with 16, 
10 and 13% of mothers, fathers and patients, respec­
tively.
The odds ratios for the homozygous mutation were 
3.7 (CI95% =  1.5-9.1) for the mothers, 2.2 (CI95o/o =  0 .8 - 
6.3) for the fathers and 2.9 (CI95%= 1.0-7.9) for the 
patients versus the controls.
The mutation was associated with decreased M TH F- 
R activity, low plasma folate and high plasma hom o­
cysteine and red cell folate concentrations. These results
T.K.A.B. Eskes / European Journal o f  Obstetrics & Gynecology and Reproductive Biology 71 (1997) 105-111 109
were confirmed by the study of Whitehead et al. (1995) 
[20].
The abnormal thermolabile allele of MTHFR can 
explain the association between elevated homocysteine 
and NTDs because of the importance of the MTHF 
role in remethylating homocysteine to methionine. It 
could in part also explain the efficacy of folic acid in 
preventing NTDs by overcoming a partial enzymatic 
block.
These studies provide evidence of a genetic explana­
tion for NTDs and suggest a mechanism whereby a 
genetic factor (the abnormal enzyme) and an environ­
mental factor (folic acid) interact.
Posey et al. (1996) [21] calculated (based upon the 
available literature) that 13% of NTD cases can be 
attributed to the homozygous 677 C -T  mutation. If 
heterozygosity is a causal risk factor for NTD an 
additional 11% of NTD cases may be attributed to the 
mutation. These fractions fall well below the 70% re­
duction in NTD rates [4]. Therefore the protective 
effect of folic acid against NTDs has to involve other 
biological and/or gene interactions as well
7. Is homocysteine toxic for the embryo?
Fetal loss has been observed in 25 of 52 pregnan­
cies of untreated homozygous CBS deficient women. 
However, these data were sampled in retrospect and 
strongly influenced by the high number of stillbirth 
and spontaneous abortions in a few individuals [22].
The teratogenic effects of an impaired methionine- 
homocysteine cycle could be due to cytogenetic dam­
age of homocysteine or insufficient methionine levels 
leading to insufficient methyldonorship, altered DNA 
synthesis or abnormalities of DNA méthylation.
A possible role of homocysteine in the aetiology of 
NTDs was tested in vitro by culturing day 10 post 
coi turn post-implantation rat embryos [23]. In high 
doses (3.6-7.2 mM/h) the mitotic index of the neural 
epithelium of the rhombencephalon as well as the to­
tal morphological score was reduced.
The embryotoxicity of L-homocysteine was 
stereospecific since D-homocysteine caused no embry- 
otoxic effects.
In lower concentrations (1 and 2 mM) however, the 
addition of L-homocysteine was not toxic and pro­
moted normal development of rat embryos. At even 
lower concentrations L-methionine had the same 
beneficial effect. Methionine is the precursor of S- 
adenosyl methionine (SAM) which is the universal 
methyldonor in transmethylation reactions and thus 
essential to normal embryonic growth and develop­
ment. As a low ratio of SAM and S-adenosylhomo- 
cysteine (SAH) will inhibit many transmethylation 
reactions [24], it is hypothesized that increased SAH
formation resulting from high homocysteine concen­
trations is the first step in the embryotoxic mecha­
nism of L-homocysteine [25].
This view is in line with the observation that L-me­
thionine deficiency induced NTD in cultured rat em­
bryos [26,27].
8. Hyperhomocystinaemia is associated with recurrent 
spontaneous miscarriage
In the products of conception, which can be stud­
ied after the spontaneous abortion process, the preva­
lence of NTD is ten-fold increased as compared to 
the prevalence at birth [28,29].
It was thei*efore, after the finding of mild hyperho- 
mocysteinaemia in NTD, not illogic to study a possi­
ble association between hyperhomocysteinaemia and 
spontaneous miscarriage.
The association between hyperhomocysteinaemia 
and recurrent early pregnancy loss could be confirmed 
[30,31],
In an extended study [32] 180 women with recur­
rent miscarriage and 46 controls were selected. Hyper­
homocysteinaemia was defined as a fasting and/or 
postmethionine load plasma homocysteine concentra­
tion above the 97.5 percentile level o f the controls, 
Hyperhomocysteinaemia was diagnosed in 22% of 
women with recurrent miscarriage and 9% in controls. 
In women with recurrent miscarriage plasma homo­
cysteine concentrations were significantly and nega­
tively correlated to blood concentrations of folate and 
vitamin B12.
In the same study, enzymes were determined in a 
subset of women, CBS and thermolabile 5,10-MTHF- 
R. CBS activity in fibroblasts was within the range of 
obligate heterozygotes and thermolabile M TH FR  in 
isolated lymphocytes was observed in one out of seven 
and three out of 17 hyperhomocysteinemic women with 
recurrent miscarriage, respectively.
Hyperhomocysteinaemia could be corrected by 
daily oral administration of 1 nig folic acid.
The rate of live births in a subsequent pregnancy 
was 83% in hyperhomocysteinemic women who were 
treated with B-vitamins, In 17 normohomocysteinemic 
women using B-vitamins as well the rate was 65%. In 
55 normohomocysteinemic women who had not used 
any vitamins the rate was 53%.
A randomized controlled prevention trial should 
provide the answer to the intiiguing question if vita­
min B supplementation prevents spontaneous abor­
tion (at least in a subset of women). Such a trial 
however is hampered by the fact that folic acid (mul­
tivitamins) prevents the occurrence and recurrence of
NTD.
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9. Multivitamins (folic acid) reduce also the rate of 
congenital anomalies other than NTDs
Periconceptional multivitamin supplementation can 
reduce not only the rate of NTDs but also the rate of 
other major non-genetic syndromatic congenital abnor­
malities [33].
Maternal periconceptional use of multivitamins re­
duces the risk for conotruncal heart defects and limb 
deficiencies [34], schisis [35] and urinary tract anomalies 
[36].
10. Consumption of extra natural food folate is less 
effective for folate status than folic acid 
supplementation
The findings of the M RC vitamin study group [4] led 
the UK Department ,of Health to recommend that 
women of child-bearing age should consume 400 jug of 
folic acid or folate per day to prevent NTD [37]. These 
recommendations were also made in the USA [38], the 
Netherlands [39] and in Australia [40].
These recommendations make the assumption that 
all routes of intervention like supplements, folic acid 
fortification natural food folates and dietary advice 
have similar potential to optimise folate metabolism.
The effect of increasing dietary folate on red-cell 
folate was studied by Cuskelly et al. [41]. They assessed 
the effectiveness of folic acid supplement (400 jig per 
day), folic-acid-fortified foods (400 /¿g/day added), di­
etary folate (an additional 400 jig per day), dietary 
advice and controls. Red cell folate increased signifi­
cantly over a 3 month period only in the groups taking 
folic acid supplements or food fortified with folic acid. 
Dietary folate or dietary advice did not change the 
folate status.
Synthetic folates (folic acid) have the advantage of a 
greater stability and better absorption than dietary 
folates. Folic acid is not just more stable than natural 
folates (polyglutamates) but it has twice the 
bioavailability [42], Also, prolonged cooking destroys 
some of the natural food folates.
It therefore seems that folic acid supplementation as 
a tablet or enrichment of food is the most effective way 
of ameliorating folate status. The USA plans to add 
folic acid to food products [43].
The fortification of food supply with folic acid is 
challenged by Gaull et al. (1996) [44]. These authors 
discuss the uncertainties like the fact that NTDs seem 
to-be a multifactorial polygenic group of disorders so 
that folate will not help in all cases. In various coun­
tries the incidence of NTDs is decreasing. For those not 
at risk folate may pose safety concerns. There is not yet 
established a dose-response relationship between folate 
and NTDs. Finally, pharmacological doses of a nutri­
ent may be required in case of a metabolic abnormality.
It seems to us that the described MTHFR deficiency 
group fulfils the criteria of these authors.
In conclusion, we can state that the periconceptional 
use of folic acid reduces the occurrence and recurrence 
of NTDs substantially. A possible defect of folate 
metabolism can be diagnosed by determining homocys­
teine in serum, or more directly by demonstrating ther­
molabile 5,10-MTHFR. A subgroup of women who 
experienced NTD do have hyperhomocysteinaemia and 
a mutation of this M THFR gene.
Homocysteine seems to be involved in the pathogene­
sis of NTD. The reduction of homocysteine by stimula­
tion of residual enzyme activity by folates (and/or 
Vitamin BJ2) could be an explanation for the effect of 
folate on NTD occurrence and recurrence.
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